Dynavax to Present at the 2018 Cantor Global Healthcare Conference

BERKELEY, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation DVAX today announced that Eddie Gray, Dynavax's Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental New York Barclay Hotel.

The live and replayed versions of the webcast will be available on the "Events and Presentations" section of the Dynavax website at http://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in January 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.

Contact:

Ryan Spencer

VP Corporate Strategy and Communications

510.665.4608